BeautyHealth Stock Receives Mixed Analyst Outlook Amid Recent Gains

Beauty Health Co shares are trading slightly higher in early market activity, buoyed by fresh commentary from financial analysts. While the overall sentiment remains cautious, some firms are pointing to potential recovery signs for the specialty aesthetics company.

Expressing notable confidence, Roth Capital commenced coverage of Beauty Health on Friday with a Buy recommendation. Analyst George Kelly set a price target of $3.50, citing the company’s successful management restructuring and financial estimates he views as overly conservative. The firm anticipates that cost-saving initiatives and new product launches scheduled for late 2025 and 2026 will provide significant momentum.

TD Cowen Maintains Caution Despite Target Increase

In a contrasting move, TD Cowen adjusted its valuation on Tuesday, raising the... Read more...